About

NaviGate Cardiac Structures, Inc.

NaviGate Cardiac Structures, Inc., (NCSI) is focused on developing transcatheter solutions for treatment of atrioventricular valve regurgitation. NCSI’s valve-based technology was licensed from Cleveland Clinic and further modified and developed by NCSI.

The GATE™ Valve

The NCSI Team

The leadership team at NCSI includes a core group of professionals with considerable experience and expertise in the development of surgical and transcatheter replacement heart valves. You can learn more about NCSI’s leadership team below.

R.C. Quijano

CEO

Read More

R.C. Quijano, MD/PhD – Founded Xenomedica AG, Switzerland; VP R&D, Regulatory and Clinical Affairs Edwards CVS; Founded VenPro Corp. venous valves replacement and first valve ever implanted in a human (now Melody, MDT) by catheter guided means; Founder 3f Therapeutics; Founder NaviGate Cardiac Structures, Inc. Over 30 years experience in replacement heart valves.

Neville Jeharajah

CFO

Read More

Neville Jeharajah – CFO, V.P., Finance and Operations, Edwards Heart Valves; Baxter Healthcare Corp, Corporate Financial Planning, and Corporate Officer; Strategic and Operational Planning. Over 25 years experience.

Thomas Humphrey

Global VP of Regulatory Affairs and Quality Assurance

Read More

Thomas Humphrey – Global VP of Regulatory Affairs and Quality Assurance – With more than three decades of experience focusing on cardiovascular medical devices, Mr. Humphrey’s experience in the medical device industry has included responsibility for Regulatory, Quality and Clinical Affairs for surgical and transcatheter heart valve programs.  Prior to joining Navigate Cardiac Structures, Inc., Mr. Humphrey served as Director of Regulatory, Quality and Clinical Affairs at 3F Therapeutics, Inc. and Director of Regulatory Affairs at Edwards Lifesciences LLC.

Kalathi Thyagarajan

Vice President, Clinical Affairs

Read More

Kalathi Thyagarajan, Vice President, Clinical Affairs with 30+ years of experience in Biological Heart Valves in various manufacturers, including Meadox Medical (Shelhigh Valves), Edwards Cardiovascular Surgery, VenPro, Director of Research; 3F Therapeutics, CoreValve Percutaneous Aortic Valve V.P., RA/QA and CardiAQ Valve Technologies, VP RA/QA.

Matthew Pollman

Executive Vice President

Read More

Matthew Pollman, M.D., Executive Vice President, Founder/President/CSO CV Ingenuity; Medical Director Abbott Vascular; Director New Ventures Guidant; Director Cardiovascular Biology Millennium Pharmaceuticals. Over 25 years of experience.